(Side) effects of VEGF inhibition;(Neben-) wirkungen der VEGF-inhibition

Ophthalmologe

Volumn 103, Issue 6, 2006, Pages 484-492

  Ziemssen, F ^a   Bartz Schmidt, K U ^a   Grisanti, S ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bevacizumab (Avastin ); Endophthalmitis; Hypertension; Pegaptanib sodium (Macugen ); Ranibizumab (Lucentis ); Side effects; VEGF

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN;

CLINICAL TRIAL; ENDOCRINOLOGY; HEMATOPOIESIS; HEMODYNAMICS; HUMAN; IMMUNE SYSTEM; LYMPHOID CELL; RETINA MACULA EDEMA; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 33745167398     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-006-1354-3     Document Type: Review

References (31)

1. European public assessment report (2006)http://www.emea.eu.int/humandocs/ Humans/EPAR/macugen/macugen.htm
2. Alon T, Hemo I, Itin A et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1(10): 1024-1028
3. Avery RL, Pieramici DJ, Rabena MD et al. (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3): 363-372
4. Baffert F, Thurston G, Rochon-Duck M et al. (2004) Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ Res 94(7): 984-992
5. Bates DO, Jones RO (2003) The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds 2(2): 107-120
6. Campochiaro PA (2006) Ocular versus extraocular neovascularization: mirror images or vague resemblances. Invest Ophthalmol Vis Sci 47(2): 462-474
7. Clauss M, Gerlach M, Gerlach H et al. (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172(6): 1535-1545
8. Fung AE, Rosenfeld PJ, Reichel EZ (2006) Intravitreal Avastin Safety Survey: Results From the World Wide Web. Invest Ophthalmol Vis Sci 47: A5251
9. Gabrilovich D, Ishida T, Oyama T et al. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92(11): 4150-4166
10. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V (2005) Preclinical pharmacokinetics of Ranibizumab (rhu-FabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 46(2): 726-733
11. Glusker P, Recht L, Lane B (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9): 980-982
12. Gora-Kupilas K, Josko J (2005) The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropathol 43(1): 31-39
13. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27): 2805-2816
14. Greenberg DA, Jin K (2005) From angiogenesis to neuropathology. Nature 438(7070): 954-959
15. Hariprasad SM, Shah GK, Blinder KJ (2006) Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection. Am J Ophthalmol 141(1): 200-201
16. Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342
17. Kaiser P, ANCHOR Study Group (2006) ANCHOR DATA (year one results). Macula 2006, paper presentation, New York/NY, USA
18. Kamba T, Tam BY, Hashizume H et al. (2006) VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290(2): H560-H576
19. Ma L, Francia G, Viloria-Petit A et al. (2005) In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 65(12): 5365-5373
20. Maharaj AS, Saint-Geniez M, Maldonado AE, D'Amore PA (2006) Vascular endothelial growth factor localization in the adult. Am J Pathol 168(2): 639-648
21. Marneras AG, Fan J, Yokoyama Y et al. (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 167(5): 1451-1459
22. Maynard SE, Min JY, Merchan J et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111(5): 649-658
23. Ostendorf T, Kunter U, Eitner F et al. (1999) VEGF(165) mediates glomerular endothelial repair. J Clin Invest 104(7): 913-923
24. Samson M, Peale FV, Frantz G et al. (2004) Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. J Clin Endocrinol Metab 89(8): 4078-4088
25. Scappaticci FA, Fehrenbacher L, Cartwright T et al. (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3): 173-180
26. Shima DT, Nishijima K, Jo N, Adamis AP (2004) VEGF-mediated neuroprotection in ischemic retina. Invest Ophthalmol Vis Sci 45: A3270
27. Shimizu T, Sato E (2005) Manipulation of ovarian follicle development by injecting vascular endothelial growth factor (VEGF) gene. Reprod Biol 5(3): 257-268
28. Spaide RF, Armstrong D, Browne R (2003) Continuing medical education review: choroidal neovascularization in age-related macular degeneration - what is the cause? Retina 23(5): 595-614
29. Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7(4): 335-345
30. Yang R, Thomas GR, Bunting S et al. (1996) Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27(6): 838-844
31. Ziemssen F, Warga M, Neuhann IM et al., Tuebingen Bevacizumab Study Group (2006) Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? Br J Ophthalmol, in press